Mecasermin
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Mecasermin: From Severe Primary IGF-1 Deficiency to Monosomy X
One-Sentence Summary
Mecasermin (recombinant human IGF-1) is a growth-factor replacement therapy; DrugBank record confirms the compound but no approved-indication text is on file for this market. The TxGNN model predicts a possible link to Monosomy X (Turner syndrome), but this is a pure knowledge-graph inference with zero supporting clinical trials or literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (no Taiwan/US license on file). Per the drug’s own repurposing rationale, mecasermin is a recombinant IGF-1 originally developed for severe primary IGF-1 deficiency (Laron-type growth hormone insensitivity) |
| Predicted New Indication | Monosomy X (Turner syndrome) |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 (model prediction only, no clinical or literature support) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (drug-level MOA is marked as a data gap, DG002). Based on known information, mecasermin is a recombinant human IGF-1 (rhIGF-1) molecule that acts downstream of the growth hormone receptor, replacing IGF-1 directly rather than stimulating its endogenous production.
Turner syndrome (monosomy X) commonly presents with growth retardation and a partial growth-hormone-resistant phenotype, and the GH-IGF1 axis is an established target for growth-promoting therapy in this population — which gives the prediction a plausible physiological rationale. However, the evidence pack itself flags this link as an indirect, graph-based association only (“需先查證是否已有真實世界文獻，本次收集未涵蓋”), with no clinical trial or publication data collected to confirm it.
Notably, a lower-ranked candidate in this same evidence pack — growth hormone insensitivity syndrome with immune dysregulation 2 (rank 3, score 99.06%) — sits mechanistically much closer to mecasermin’s known original use (it belongs to the same GHR/STAT5 signaling-defect disease family the drug was designed to bypass), but it likewise has no clinical trial or literature evidence in this dataset. Two other candidates (esophageal varices, with/without bleeding) are assessed in the source rationale as likely false positives driven by an indirect comorbidity association (low IGF-1 as a consequence of cirrhosis, not a treatment target) and are not further discussed here.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA label warnings/contraindications and formal DDI data are currently unavailable and are flagged in the source evidence pack as a Blocking data gap (DG001) that prevents this candidate from entering safety pre-screening (S1).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but the evidence level is L5 — a pure TxGNN model output with no clinical trials, no literature, and no route-compatibility data. Combined with a Blocking-severity gap in TFDA safety/label data, this candidate cannot yet proceed past the research-question stage.
To proceed, the following is needed:
- TFDA package insert / label warnings and contraindications (DG001, blocking)
- DrugBank/API-sourced mechanism of action detail (DG002)
- A dedicated literature and real-world-evidence search for IGF-1 use in Turner syndrome (not covered by this data collection run)
- Route-compatibility assessment (currently “pending”)
- Consider evaluating the mechanistically closer candidate (GH insensitivity syndrome with immune dysregulation) in parallel, as it aligns more directly with mecasermin’s known biology
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.